Clinical Trial Results Comparison Three landmark Phase 3 trials provide the comparison data
The clinical trial data from SURMOUNT-1 enrolled participants with a mean BMI of 38, and the results showed dramatic weight loss outcomes across dosing tiers
The app includes weight logging, a trend chart, five food logging methods, side effect tracking across the 18 most common GLP-1 side effects, plus unlimited custom symptoms, the weekly checklist, Journey Cards, and the home screen widget
Hormonal Modulation Retas unique ability to interact with multiple receptor types provides a framework for studying hormonal cross-talk, especially how GLP-1, GIP, and glucagon signaling affect one another in metabolic tissues
February 12, 2025
"People can lose more fat." Retatrutide: Next-gen obesity drug helps patients lose 28% of body weight In a phase-three trial by Eli Lilly, patients on the highest dose lost an average of 28.3% of their body weight over a year and a half, and more than 45% of participants lost at least 30%, a level of efficacy the company said approaches results seen with bariatric surgery
